Unnatural Products Inc. Email Format
Biotechnology ResearchCalifornia, United States51-200 Employees
Unnatural Products Inc. is a biotechnology research company headquartered in Santa Cruz, California, employing 51 to 200 people. The company focuses on macrocycle drug discovery using machine learning and massively parallel synthesis to advance therapeutic candidates. It develops orally delivered macrocyclic peptide therapeutics aimed at targets that have been difficult to drug. In March 2026, the company announced the closing of a Series B financing led by The Venture Collective with participation from investors including argenx and Droia Ventures. In February 2026, Novartis Pharmaceuticals Corporation entered into a research partnership and licensing agreement with Unnatural Products, valued at up to $1.7 billion, to develop macrocyclic peptide therapeutics for cardiovascular diseases. The company maintains a presence online at https://unnaturalproducts.com.